vs
Side-by-side financial comparison of Travere Therapeutics, Inc. (TVTX) and Vroom, Inc. (VRM). Click either name above to swap in a different company.
Vroom, Inc. is the larger business by last-quarter revenue ($235.9M vs $129.7M, roughly 1.8× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 12.9%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs -49.5%).
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
Vroom, Inc. is a parent company of United Auto Credit Corporation (UACC) and CarStory. Previously, Vroom was a used car retailer and e-commerce company that let consumers buy, sell, and finance cars online. Vroom ceased e-commerce automotive sales operations on January 22, 2024.
TVTX vs VRM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $129.7M | $235.9M |
| Net Profit | — | $-141.1M |
| Gross Margin | 98.0% | 12.3% |
| Operating Margin | -25.0% | -11.5% |
| Net Margin | — | -59.8% |
| Revenue YoY | 73.4% | 12.9% |
| Net Profit YoY | — | -669.8% |
| EPS (diluted) | $0.04 | $-80.66 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $129.7M | — | ||
| Q3 25 | $164.9M | — | ||
| Q2 25 | $114.4M | — | ||
| Q1 25 | $81.7M | — | ||
| Q4 24 | $74.8M | — | ||
| Q3 24 | $62.9M | — | ||
| Q2 24 | $54.1M | — | ||
| Q1 24 | $41.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | $25.7M | — | ||
| Q2 25 | $-12.8M | — | ||
| Q1 25 | $-41.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-54.8M | — | ||
| Q2 24 | $-70.4M | — | ||
| Q1 24 | $-136.1M | — |
| Q4 25 | 98.0% | — | ||
| Q3 25 | 99.0% | — | ||
| Q2 25 | 98.7% | — | ||
| Q1 25 | 94.3% | — | ||
| Q4 24 | 96.6% | — | ||
| Q3 24 | 97.4% | — | ||
| Q2 24 | 96.2% | — | ||
| Q1 24 | 96.4% | — |
| Q4 25 | -25.0% | — | ||
| Q3 25 | 15.1% | — | ||
| Q2 25 | -11.1% | — | ||
| Q1 25 | -52.2% | — | ||
| Q4 24 | -81.2% | — | ||
| Q3 24 | -89.3% | — | ||
| Q2 24 | -125.1% | — | ||
| Q1 24 | -336.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | 15.6% | — | ||
| Q2 25 | -11.1% | — | ||
| Q1 25 | -50.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -87.1% | — | ||
| Q2 24 | -130.1% | — | ||
| Q1 24 | -328.9% | — |
| Q4 25 | $0.04 | — | ||
| Q3 25 | $0.28 | — | ||
| Q2 25 | $-0.14 | — | ||
| Q1 25 | $-0.47 | — | ||
| Q4 24 | $-0.71 | — | ||
| Q3 24 | $-0.70 | — | ||
| Q2 24 | $-0.91 | — | ||
| Q1 24 | $-1.76 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $93.0M | $135.6M |
| Total DebtLower is stronger | — | $454.2M |
| Stockholders' EquityBook value | $114.8M | $127.7M |
| Total Assets | $605.2M | $1.5B |
| Debt / EquityLower = less leverage | — | 3.56× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.0M | — | ||
| Q3 25 | $110.9M | — | ||
| Q2 25 | $75.2M | — | ||
| Q1 25 | $61.9M | — | ||
| Q4 24 | $58.5M | — | ||
| Q3 24 | $36.4M | — | ||
| Q2 24 | $32.3M | — | ||
| Q1 24 | $43.3M | — |
| Q4 25 | $114.8M | — | ||
| Q3 25 | $73.6M | — | ||
| Q2 25 | $32.7M | — | ||
| Q1 25 | $32.8M | — | ||
| Q4 24 | $59.1M | — | ||
| Q3 24 | $-30.5M | — | ||
| Q2 24 | $15.1M | — | ||
| Q1 24 | $74.1M | — |
| Q4 25 | $605.2M | — | ||
| Q3 25 | $538.6M | — | ||
| Q2 25 | $555.3M | — | ||
| Q1 25 | $548.8M | — | ||
| Q4 24 | $594.1M | — | ||
| Q3 24 | $504.4M | — | ||
| Q2 24 | $551.1M | — | ||
| Q1 24 | $663.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.7M | $-108.1M |
| Free Cash FlowOCF − Capex | — | $-108.8M |
| FCF MarginFCF / Revenue | — | -46.1% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-536.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.7M | — | ||
| Q3 25 | $14.3M | — | ||
| Q2 25 | $5.0M | — | ||
| Q1 25 | $-42.2M | — | ||
| Q4 24 | $-35.7M | — | ||
| Q3 24 | $-42.5M | — | ||
| Q2 24 | $-40.2M | — | ||
| Q1 24 | $-119.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | $14.2M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-40.3M | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 8.6% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -74.5% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.56× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
VRM
Segment breakdown not available.
